Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

NCT05084859 is registered in ClinicalTrials.gov with Biosplice Therapeutics, Inc. as lead sponsor.

NCT NCT05084859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05084859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Lead sponsor
Biosplice Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 3, 2021
Completion date
October 20, 2022
Enrollment
30 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, colorectal cancer, non-small cell lung cancer